|UNAIDS-Sponsored Regional Workshops to Discuss Ethical Issues in Preventive HIV Vaccine Trials (UNAIDS, 2000, 52 p.)|
|ENTEBBE, UGANDA, 27-29 APRIL, 1998|
In general, an HIV vaccine manufacturer will have claim to intellectual property (patent and trademark). However, there may be situations in which the contribution of the host country to the vaccine development process is significant enough to justify the country having claim to intellectual property. An arrangement should be negotiated prior to conducting the trial.
A host country might consider negotiating technology transfer, recognition of stakeholders in publications, a claim to spin-off developments (such as new assays or other scientific advances) or a share of the proceeds resulting from sale of the vaccine.